Publication:
Cardiac effects of dapagliflozin in diabetic rats with subacute exposure

Simple item page
dc.contributor.authorERCAN, FERİHA
dc.contributor.authorsBoran T., Karaca B. U., Koroglu A. K., Kaptan E., Ercan F., Özhan G.
dc.date.accessioned2023-06-13T08:36:43Z
dc.date.accessioned2026-01-11T09:23:55Z
dc.date.available2023-06-13T08:36:43Z
dc.date.issued2022-04-01
dc.description.abstractBackground and Aims: Dapagliflozin (DAPA) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus (T2DM) as a monotherapy or combination therapy with other antidiabetic medicines. The Food and Drug Administration (FDA) recently approved DAPA to minimize the risk of hospitalization due to heart failure in patients with T2DM because of its antihypertensive and antihyperglycemic activities. However, further study of DAPA is necessary to ensure the safety of patients.
dc.identifier.citationBoran T., Karaca B. U., Koroglu A. K., Kaptan E., Ercan F., Özhan G., "Cardiac effects of dapagliflozin in diabetic rats with subacute exposure", ISTANBUL JOURNAL OF PHARMACY, cilt.52, sa.1, ss.8-13, 2022
dc.identifier.doi10.26650/istanbuljpharm.2022.1038546
dc.identifier.endpage13
dc.identifier.issn2587-2087
dc.identifier.issue1
dc.identifier.startpage8
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/b6ca52b5-7670-40d0-951a-51d9eea54c6a/file
dc.identifier.urihttps://hdl.handle.net/11424/290230
dc.identifier.volume52
dc.language.isoeng
dc.relation.ispartofISTANBUL JOURNAL OF PHARMACY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectHealth Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectNatural Sciences
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectFarmakoloji
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectPharmacology (medical)
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectDapagliflozin
dc.subjectSGLT2 inhibitor
dc.subjectType 2 diabetes mellitus
dc.subjectCardio-protection
dc.subjectGLUCOSE COTRANSPORTER 2
dc.subjectOXIDATIVE STRESS
dc.subjectSGLT2 INHIBITOR
dc.subjectTROPONIN-T
dc.subjectCARDIOMYOPATHY
dc.subjectDIET
dc.subjectDapagliflozin
dc.subjectSGLT2 inhibitor
dc.subjectType 2 diabetes mellitus
dc.subjectCardio-protection
dc.titleCardiac effects of dapagliflozin in diabetic rats with subacute exposure
dc.typearticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
739.13 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları